Elsevier

European Urology

Volume 49, Issue 1, January 2006, Pages 183-186
European Urology

Case Study of the Month
Metastatic Spermatocytic Seminoma – An Extremely Rare Disease

https://doi.org/10.1016/j.eururo.2005.08.020Get rights and content

Abstract

Metastatic spermatocytic seminoma is an extremely rare disease with only one documented case in literature. We present another patient with metastatic disease confirmed by histological work-up after laparoscopic retroperitoneal lymph node dissection (L-RPLND).

Section snippets

Case report

In March 2002, a previously healthy 26-year-old man underwent right orchiectomy for an intratesticular tumor of 7cm in diameter. Diagnosis of a spermatocytic seminoma with vessel invasion without sarcomatous elements (stage pT2 V1 R0) was made based on typical histomorphological features (Fig. 1A) and detailed immunohistochemical analyses (negative staining: vimentin, actin, desmin, α-fetoprotein [AFP], beta human chorionic gonadotropin [βhCG], CD3, CD5, CD20, CD30, CD56, cytokeratin-CAM.5.2,

EU-ACME Question

Please visit www.eu-acme.org to answer the below EU-ACME question on-line (the EU-ACME credits will be attributed automatically). The answer will be printed at the end of next month's Case Study of the Month.
Question:

Which statement concerning spermatocytic seminoma is correct?

  • A)

    Spermatocytic seminoma accounts for ∼20% of seminomas and is predominately found in patients between 17 and 25 years of age.

  • B)

    As in classical seminoma PLAP staining is positive in spermatocytic seminoma.

  • C)

    Spermatocytic

Acknowledgements

The authors gratefully acknowledge the reference expertise of Margaret C. Parkinson from the Department of Histopathology, University College London Medical School, Great Britain.

References (1)

  • I. Verdorfer et al.

    Molecular cytogenetic analysis of human spermatocytic seminomas

    J Pathol

    (2004)

Cited by (32)

  • Testicular Tumors: New Developments in Germ Cell and Sex Cord Stromal Tumors

    2022, Surgical Pathology Clinics
    Citation Excerpt :

    This is reported in relation to sarcomatous transformation and very recently identification of STs with hybrid genetics characterized by chromosome 12p amplification, a highly unusual and intriguing finding. Authors have found lymphovascular invasion in these cases and speculated that gain of 12p might be linked to metastatic potential in STs analogous to this phenomenon in GCNIS-derived GCTs.43,46–49 Further research is needed to define possible biomarkers of aggressive clinical behavior in this otherwise benign tumor.50

  • Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants

    2022, Human Pathology
    Citation Excerpt :

    These tumors frequently exhibit gains of chromosome 12p/isochromosome 12p and have malignant behavior [9]. Interestingly, of the 5 reported metastatic STs without sarcomatoid transformation, gain of chromosome 12p was identified in 2 (of 3) tumors that were tested (Wagner et al. and Mikuz et al.) [5,12–15]. Although the original study by Matoska et al. [15] did not evaluate chromosome 12p gain in a metastatic nonsarcomatoid tumor, the cytogenetics of this tumor were evaluated in a follow-up study by Verdorfer et al. and no gain of chromosome 12p was identified [8].

  • Testis and paratestis including spermatic cord

    2009, Modern Surgical Pathology
  • Testis and Paratestis Including Spermatic Cord

    2009, Modern Surgical Pathology
View all citing articles on Scopus
View full text